

NAME: Report,Gastro
ACC #: P241070003
DOB: 1/1/2001

SEX:

SPECIMEN DETAILS

SPECIMEN TYPE: Buccal Swab

COLLECTION DATE: 4/16/2024 4:14 PM

RECEIVED DATE: 4/16/2024 4:17 PM

REPORT DATE: 4/16/2024

PROVIDER INFORMATION

ORDERING PHYSCIAN: Doctor Test

PROVIDER:



Pharmacogenomic Test

Thank you for choosing Omni Health Diagnostics Test. This report contains four color-coded sections to easily show whether there is a genetic predisposition that may affect the patient's response to drugs or indicate the potential for adverse effects.



Rx Medication Review

a list of prescribed drugs and any gene or drug interactions



Drug Guide

a drug focused report by therapeutic category



Summary of Genes Tested

a summary of your results for all genes tested.



Detailed Explanation of Findings

a more informative view of drug and gene relationships

This is a matrix of all drugs currently prescribed and contemplated. The matrix determines if there is any drug-to-drug or drug-to-gene interaction for the medications provided. Visit the online portal to view how any changes to these drugs may impact risk of drug-to-drug or drug-to-gene interactions.

We illustrate the impact of the tested genes on the most commonly prescribed medications. Simply identify therapeutic category of interest and review the impact of genetics on these drugs listed by medication name (both brand and generic). The impact of genetics as shown in the drug guide is derived by considering ALL tested genes that are relevant for each listed drug (also called combinatorial pharmacogenetics).

We show the patient's genotype and phenotype for each of the genes tested. This summary helps to quickly understand how your genes are impacting your medication's effectiveness.

We look at each gene separately and explains how the genotype and phenotype may impact drug responses. For each tested gene, the report shows how the phenotype impacts drugs, along with a list of the most commonly prescribed drugs affected by each gene.

Accession: P241070003

Page: 1 of 17



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

Molecular PGX PGx - Gastroenterology Panel Report

Current Patient Medications: All provided medications as of 4/16/2024

4

omeprazole (Prilosec) - Potential risk (CYP2C19: Intermediate Metabolizer)



rabeprazole (Aciphex)

omeprazole (Prilosec)

rabeprazole (Aciphex) - Potential risk (CYP2C19: Intermediate Metabolizer)



Bismuth carbonate

Bismuth carbonate - Standard Precautions



clarithromycin (Biaxin)

clarithromycin (Biaxin) - Standard Precautions



Milk of magnesia

Milk of magnesia - Standard Precautions

*Note: DDI = Drug-Drug Interactions as found by DrugBank

GUIDANCE LEVELS



A medication has potentially reduced efficacy, increased toxicity or the patient has an increased risk for the indicated condition.



Guidelines exist for adjusting dosage, increased vigilance or the patient has a moderate risk for indicated condition.



The medication can be prescribed according to standard regimens or the patient's risk for the indicated condition is not increased.

Patient: Report, Gastro

© Copyright SmartPGX, LLC 2024. All rights reserved.

Accession: P241070003

Page: 2 of 17



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

Potentially Impacted Medications:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Category	Drug Class	Standard Precaution	Use With Caution	Consider Alternatives
Antidiabetic		glimepiride (Amaryl) glipizide (Glucotrol) glyburide (Diabeta, Micronase) Chlorpropamide (Diabinese) tolbutamide (Orinase) Nateglinide (Starlix) Repaglinide (Prandin, Prandimet)		
Anti-Infectives		ritonavir (Norvir) indinavir (Crixivan) clarithromycin (Biaxin) efavirenz (Sustiva) erythromycin (E-Mycin) saquinavir (Invirase) telithromycin (Ketek)	nelfinavir (Viracept)	
Cardiovascular	Antianginal	ranolazine (Ranexa)		
	Antiarrhythimcs	flecainide (Tambocor) propafenone (Rythmol) quinidine (Quinidine) Mexiletine (Mexitil) Amiodarone (Nexterone, Pacerone) dofetilide (Tikosyn) Sotalol (Betapace, Sorine, Sotylize) Disopyramide (Norpace)		
	Anticoagulants	warfarin (Coumadin, Jantoven) rivaroxaban (Xarelto) Prasugrel (Effient) ticargelor (Brilinta) Betrixaban (Bevyxxa) Apixaban (Eliquis) Vorapaxar (Zontivity)	clopidogrel ++ (Plavix)	



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Category	Drug Class	Standard Precaution	Use With Caution	Consider Alternatives
category	Antihypertensive	propanolol (Inderal) metoprolol (Lopressor, Toprol) nebivolol (Bystolic) Candesartan cilexetil (Atacand) Irbesartan (Avapro) timolol (Blocadren) losartan (Cozaar, Hyzaar) carvedilol (Coreg) diltiazem (Cardizem) amlodipine (Norvasc) felodipine (Plendil) Olmesartan (Benicar) Bisoprolol (Zebeta) Atenolol (Tenormin) Labetalol (Normodyne, Trandate) Valsartan (Diovan, Entresto) nifedipine (Adalat, Procardia) nisoldipine (Sular) nitrendipine (Baypress) lercanidipine (Zanidip) Telmisartan (Micardis)	Azilsartan medoxomil (Edarbi, Edarbyclor)	CONSIDER ARCHITECTURES
Cholinesterase Inhibitors	Cholesterol Lowering	fluvastatin (Lescol) atorvastatin (Lipitor, Caduet) rosuvastatin (Crestor) simvastatin (FloLip, Zocor) pravastatin (Pravachol) lovastatin (Mevacor, Altoprev, Advior) Donepezil (Aricept) Rivastigmine (Exelon)		
Controlintostinol		Galantamine (Razadyne, Reminyl) Memantine (Namenda)	ocomonyanala (Navisus)	
Gastrointestinal			esomeprazole (Nexium) lansoprazole (Prevacid) omeprazole (Prilosec) pantoprazole (Protonix) rabeprazole (Aciphex) Dexlansoprazole (Dexilant, Kapidex)	



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Category	Drug Class	Standard Precaution	Use With Caution	Consider Alternatives
lmmunological	Antiemetics	Dolasetron (Anzemet) Dronabinol (Marinol) Metoclopramide (Reglan) Ondansetron (Zofran, Zuplenz) Granisetron (Sancuso, Sustol) Aprepitant (Emend-oral) Rolapitant (Varubi) zafirlukast (Accolate) cyclosporine (Gengraf) hydrocortisone tacrolimus (Prograf,		
		Protopic)		
	Cholinergic Agonists	Cevimeline (Evoxac)		
	Selective Immunosuppressants	Siponimod (Mayzent)		
Infections	Antifungals		Voriconazole (Vfend)	
		Itraconazole (Sporanox) Fluconazole (Diflucan)		
Miscellaneous Metabolic Agents		Eliglustat (Cerdelga)		
Neuropsychiatric	ADHD Drug	Clonidine (Kapvay) Dextroamphetamine (Dexadrine) atomoxetine (Strattera) amphetamine (Adderall, Evekeo) Lisdexamfetamine (Vyvanse) Methylphenidate (Ritalin, Aptensio XR, Concerta, Metadate, Quillivant ER) Guanfacine (Intuniv)		
	Antiaddictives	Lofexidine (Lucemyra)		
	Anticonvulsants	phenytoin (Dilantin) Primidone (Mysoline) tiagabine (Gabitril) carbamazepine (Tegretol, Carbatrol, Epitol) Topiramate (Topamax) Levetiracetam (Keppra) Valproic acid (Topamax) Pregabalin (Lyrica) Oxcarbazepine (Trileptal, Oxtellar XR) Lamotrigine (Lamictal) Felbamate (Felbatol)		



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Category	Drug Class	Standard Precaution	Use With Caution	Consider Alternative
	Antidepressant	nortriptyline (Aventyl,Pamelor) Fluvoxamine (Luvox) paroxetine (Paxil, Brisdelle) venlafaxine (Effexor) vilazodone (Viibryd) trazodone (Oleptro) fluoxetine (Prozac, Sarafem) Protriptyline (Vivactil) Maprotiline (Ludiomil) Vortioxetine (Trintellix) desipramine (Norpramin) desvenlafaxine (Pristiq) buproprion (Wellbutrin, Zyban) mirtazapine (Remeron)	doxepin (Sinequan, Silenor, Prudoxin, Zonalon) citalopram (Celexa) clomipramine (Anafranil) amitriptyline (Elavil) Trimipramine (Surmontil) imipramine (Tofranil) escitalopram (Lexapro) sertraline (Zoloft)	
	Antiemetics	nefazodone (Serzone) Meclizine (Antivert)		
	Antipsychotic	quetiapine (Seroquel) risperidone (Risperdal) Pimozide (Orap) perphenazine (Trilafon) Fluphenazine (Prolixin) Iloperidine (Fanapt) thioridazine (Mellaril) haloperidol (Haldol) Brexpiprazole (Rexulti) aripiprazole (Abilify, Aristada) asenapine (Saphris) clozapine (Clozaril) chlorpromazine (Thorazine) lurasidone (Latuda) ziprasidone (Geodon) Cariprazine (Vraylar) promazine (Sparine) olanzapine (Zyprexa)		
	Anxiolytic	zolpidem (Ambien) alprazolam (Xanax) buspirone (BuSpar) Clonazepam (Klonipin) triazolam (Halcion) midazolam (Versed)	phenobarbital Clobazam (Onfi) diazepam (Valium)	
	Other	Dextromethorphan (Nuedexta) Tetrabenazine (Xenazine) Valbenazine (Ingrezza)		
	Pain Management	duloxetine (Cymbalta)		



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Drug Class	Standard Precaution	Use With Caution	Consider Alternatives
Precognitive Drug	tacrine (Cognex)		
	ifosfamide (Ifev)		
	vincristine (Vincasar,		
	docetaxel (Taxotere)		
	caffeine theophylline (Theo-24, Elixophylline, Theochron)		
t	Acetylsalicylic acid (Aspirin)		
Muscle Relaxant	Milnacipran (Savella) cyclobenzaprine (Flexaril, Amrix) Methocarbamol (Robaxin) tizanidine (Zanaflex)		
NSAID	Flurbiprofen (Ansaid, Ocufen) Piroxicam (Feldene) Diclofenac (Voltaren) Indomethacin (Indocin, Tivorbex) celecoxib (Celebrex) Meloxicam (Mobic) naproxen (Aleve) ibuprofen (Advil, Motrin) Acetaminophen (Tylenol) Ketorolac (Toradol)		
	Precognitive Drug	Precognitive Drug ifosfamide (Ifex) vincristine (Vincasar, Oncovin) docetaxel (Taxotere) caffeine theophylline (Theo-24, Elixophylline, Theochron) t Acetylsalicylic acid (Aspirin) Muscle Relaxant Milnacipran (Savella) cyclobenzaprine (Flexaril, Amrix) Methocarbamol (Robaxin) tizanidine (Zanaflex) NSAID Flurbiprofen (Ansaid, Ocufen) Piroxicam (Feldene) Diclofenac (Voltaren) Indomethacin (Indocin, Tivorbex) celecoxib (Celebrex) Meloxicam (Mobic) naproxen (Aleve) ibuprofen (Advil, Motrin) Acetaminophen (Tylenol)	Precognitive Drug ifosfamide (Ifex) vincristine (Vincasar, Oncovin) docetaxel (Taxotere) caffeine theophylline (Theo-24, Elixophylline, Theochron) t Acetylsalicylic acid (Aspirin) Muscle Relaxant Milnacipran (Savella) cyclobenzaprine (Flexaril, Amrix) Methocarbamol (Robaxin) tizanidine (Zanaflex) NSAID Flurbiprofen (Ansaid, Ocufen) Piroxicam (Feldene) Diclofenac (Voltaren) Indomethacin (Indocin, Tivorbex) celecoxib (Celebrex) Meloxicam (Mobic) naproxen (Aleve) ibuprofen (Advil, Motrin) Acetaminophen (Tylenol) Ketorolac (Toradol)



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

DRUG GUIDE

These lists of drugs are categorized to reflect whether a genetic predisposition indicates that there may be issues with regard to drug response or adverse effects.

Category	Drug Class	Standard Precaution	Use With Caution	Consider Alternatives
	Opioids	codeine++ (Codeine, Fioricet with codeine) Benzhydrocodone (Apadaz) hydrocodone++ (Vicodin) meperidine (Demerol) methadone (Dolophine) oxycodone++ (Oxycontin, Percocet) tramadol++ (Ultram) fentanyl (Actiq, Duragesic, Sublimaze) Morphine (MS Contin) Hydromorphone (Dilaudid, Exalgo) Buprenorphine (Butrans, Buprenex) alfentanil (Alfenta) buprenorphine/naloxone (Suboxone, Zubsolv, Bunavail) Oxymorphone (Opana,	tapentadol (Nucynta) carisoprodol++ (Soma)	
	Other	Numorphan) lidocaine (xylocaine, Lidoderm) zolmitriptan (Zomig)		
Rheumatology	Anti Hyperuricemeics/Anti- Gout Immunomodulators	Febuxostat (Uloric) Colchicine (Mitigare) Tofacitinib (Xeljanz) Apremilast (Otezla)	Leflunomide (Arava)	
Steroids		progesterone estradiol testosterone		
Urologicals	5-Alpha Reductase Inhibitors	Finasteride (Proscar)		
	Alpha-Blockers	Tamsulosin (Flomax) Terazosin (Hytrin) Doxazosin (Cardura) Silodosin (Rapaflo)		
	Antispasmodics for OAB	Tolterodine (Tolterodine) Mirabegron (Myrbetriq) Oxybutynin (Ditropan) Darifenacin (Enablex) Solifenacin (Vesicare)		
	Erectile Dysfunction	sildenafil (Viagra) Tadalafil (Cialis) Avanafil (Stendra) Vardenafil (Levitra)		



NAME : Report, Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

++ Pro-drug; may not be effective in Poor Metabolizers due to inability to metabolize and produce active metabolite

* The enzyme encoded by this gene is a minor metabolic pathway for this drug (of minor clinical importance)

	omeprazole (Prilosec)	Potential risk (CYP2C19: Intermediate Metabolizer)
1	phenobarbital	Potential risk (CYP2C19: Intermediate Metabolizer, CYP2C9: Normal Metabolizer)
1	Dexlansoprazole (Dexilant, Kapidex)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^</u>	Azilsartan medoxomil (Edarbi, Edarbyclor)	Potential risk (CYP2C19: Intermediate Metabolizer, CYP2C9: Normal Metabolizer)
<u>^</u>	lansoprazole (Prevacid)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^</u>	escitalopram (Lexapro)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)
<u>^</u>	Clobazam (Onfi)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^</u>	diazepam (Valium)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^</u>	esomeprazole (Nexium)	Potential risk (CYP2C19: Intermediate Metabolizer)
1	Trimipramine (Surmontil)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)
<u>^</u>	nelfinavir (Viracept)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^</u>	doxepin (Sinequan, Silenor, Prudoxin, Zonalon)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)
<u>^</u>	rabeprazole (Aciphex)	Potential risk (CYP2C19: Intermediate Metabolizer)
<u>^!</u>	imipramine (Tofranil)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)
1	clomipramine (Anafranil)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)



NAME : Report,Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

<u></u> Λ	sertraline (Zoloft)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer, CYP2C9: Normal Metabolizer)
	pantoprazole (Protonix)	Potential risk (CYP2C19: Intermediate Metabolizer)
	amitriptyline (Elavil)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)
	citalopram (Celexa)	Potential risk (CYP2D6: Normal Metabolizer, CYP2C19: Intermediate Metabolizer)



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

SUMMARY OF YOUR EXTREME RISK GENES

The following is a summary of findings, including your genotype and phenotype for each of your Extreme risk genes.

Extreme Risk Genes

Gene (Genotype)

Phenotype (Gene expression)

What it means

© Copyright SmartPGX, LLC 2024. All rights reserved.

Patient: Report, Gastro Accession: P241070003

Page: 11 of 17



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

SUMMARY OF YOUR INCREASED RISK GENES

The following is a summary of findings, including your genotype and phenotype for each of your Increased risk genes.

Increased Risk Genes

Gene (Genotype)	Phenotype (Gene expression)	What it means
ABCB1 A/G	Intermediate Activity	The ABCB1 gene encodes for P-glycoprotein, an efflux pump that removes both endogenous and exogenous molecules from the interior of the cell by pumping them outside of the cell. The P-GP pump, also called the multi-drug resistance pump, is found in the intestinal epithelium, the kidneys, and the liver, and is a major contributor to the blood brain barrier. Intermediate P-GP activity results in lower than normal intracellular concentrations of molecules that are its substrates and can affect drug response and toxicity.
CYP2C19 *1/*2	Intermediate Metabolizer	This genotype predicts less than normal metabolic enzyme activity for the enzyme controlled by this gene. Increased potential for drug accumulation and adverse drug reactions. ++ Caution should be observed with pro-drugs, e.g., clopidogrel. Less than normal active metabolite formation is expected and a full effect of the drug may not be achieved.

Patient: Report, Gastro



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

SUMMARY OF YOUR NORMAL RISK GENES

The following is a summary of findings, including your genotype and phenotype for each of your Normal risk genes.

Normal Risk Genes

Gene (Genotype)	Phenotype (Gene expression)	What it means
CYP2C9 *1/*1	Normal Metabolizer	This genotype predicts normal metabolic activity for the enzyme controlled by this gene.
CYP2D6 *1/*2	Normal Metabolizer	This genotype predicts normal metabolic activity for the enzyme controlled by this gene.

Patient: Report, Gastro

© Copyright SmartPGX, LLC 2024. All rights reserved.



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

DETAILED EXPLAINATION OF YOUR CYP2D6 GENE

The following is a detailed explaination of your CYP2D6 gene, inclusing your genotype, phenotype, and a common medicines metabolized by the gene.

Normal Risk

Gene (Genotype	Phenotype (Gene expression)	What it means
CYP2D6 *1/*2	Normal Metabolizer	This genotype predicts normal metabolic activity for the enzyme controlled by this gene.
	Common Medi	cines Metabolized by CYP2D6
Drug Type	Generic Name (Brand	Name)
Anti-Infectives	indinavir (Crixivan) *,	ritonavir (Norvir) *
Cardiovascular	(Lopressor, Toprol), n	ecainide (Tambocor), lercandipine (Zandip), metoprolol ebivolol (Bystolic), propafenone (Rythmol), propanolol (Inderal), ands), timolol (Blocadren)
Neuropsychiatric	amitriptyline (Elavil), amphetamine (Adderall), aripiprazole (Abilify), asenapine (Saphris), atomoxetine (Strattera), bupropion (Wellbutrin), chlorpromazine (Thorazine), citalopram (Celexa) *, clomipramine (Anafranil), desipramine (Norpramin), desvenlafaxine (Pristiq)*, doxepin (Sinequan, Silenor,Prudoxin, Zonalon), duloxetine (Cymbalta), escitalopram (Lexapro), fluoxetine (Prozac),haloperidol (Haldol), iloperidone (Fanapt), imipramine (Tofranil), mirtazapine (Remeron) *, nortriptyline (Aventyl,Pamelor), olanzapine (Zyprexa) *, paroxetine (Paxil), perphenazine (Trilafon), quetiapine (Seroquel) *, risperidone (Risperdal), sertraline (Zoloft) *, tacrine (Cognex), thioridazine (Mellaril), trazadone (Oleptro) *, venlafaxine (Effexor)	
Oncologic	tamoxifen ++	
Pain		*, codeine++, cyclobenzaprine (Flexeril) *, hydrocodone++ ne *, oxycodone++ (Oxycontin), tiagabine (Gabitril) *, tramadol++

⁺⁺ Pro-drug; may not be effective in Poor Metabolizers due to inability to metabolize and produce active metabolite

Patient: Report, Gastro

 $\ ^{\odot}$ Copyright SmartPGX, LLC 2024. All rights reserved.

^{*} The enzyme encoded by this gene is a minor metabolic pathway for this drug (of minor clinical importance)



NAME : Report,Gastro ACC # : P241070003 **DOB :** 1/1/2001

SEX:

DETAILED EXPLAINATION OF YOUR CYP2C9 GENE

The following is a detailed explaination of your CYP2C9 gene, inclusing your genotype, phenotype, and a common medicines metabolized by the gene.

Normal Risk

Phenotype	VAIIs at it was an a	
(Gene expression)	What it means	
Normal Metabolizer	This genotype predicts normal metabolic activity for the enzyme controlled by this gene.	
Common Med	icines Metabolized by CYP2C9	
Generic Name (Brand I	Name)	
efavirenz (Sustiva) *		
carvedilol (Coreg) *, clopidogrel (Plavix) *, fluvastatin (Lescol), glimepiride (Amaryl), glipizide (Glucotrol), glyburide (Diabeta), losartan (Cozaar), rosuvastatin (Crestor), tolbutamide (Orinase), warfarin (Coumadin)		
zarlukast (Accolate)		
fluoxetine (Prozac) *,	phenytoin (Dilantin), phenobarbital	
tamoxifen (Nolvadex) *		
sildenafil (Viagra) *		
(Celebrex), ibuprofen	done *, naproxen (Aleve), tapentadol (Nucynta)	
progesterone		
	Gene expression) Normal Metabolizer Common Medi Generic Name (Brand II efavirenz (Sustiva) * carvedilol (Coreg) *, c glipizide (Glucotrol), g tolbutamide (Orinase) zarlukast (Accolate) fluoxetine (Prozac) *, tamoxifen (Nolvadex) sildenafil (Viagra) * carisoprodol celecoxit (Celebrex), ibuprofen (Advil, Motrin), methal	

⁺⁺ Pro-drug; may not be effective in Poor Metabolizers due to inability to metabolize and produce active metabolite

Patient: Report, Gastro

 $\ ^{\odot}$ Copyright SmartPGX, LLC 2024. All rights reserved.

^{*} The enzyme encoded by this gene is a minor metabolic pathway for this drug (of minor clinical importance)



Gene

PATIENT INFORMATION

NAME : Report, Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

What it means

DETAILED EXPLAINATION OF YOUR CYP2C19 GENE

Phenotype (Gene expression)

The following is a detailed explaination of your CYP2C19 gene, inclusing your genotype, phenotype, and a common medicines metabolized by the gene.

Increased Risk

CYP2C19 *1/*2	Intermediate Metabolizer	This genotype predicts less than normal metabolic enzyme activity for the enzyme controlled by this gene. Increased potential for drug accumulation and adverse drug reactions. ++ Caution should be observed with pro-drugs, e.g., clopidogrel. Less than normal active metabolite formation is expected and a full effect of the drug may not be achieved.		
		icines Metabolized by CYP2C19		
Drug Type	Generic Name (Brand I	Name)		
Antivirals, Hormo and Anti-Diabe	, , ,	nelfinavir (Viracept), progesterone *, tolbutamide (Orinase) *		
GERD	• `	esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), rabeprazole (Aciphex)		
Neuropsychiat	ric citalopram (Celexa), c Silenor,	elomipramine (Analafril) *, diazepam (Valium), doxepin (Sinequan,		
	Prudoxin, Zonalon), e perphenazine (Trilafo	scitalopram (Lexapro), imipramine (Tofranil), paroxetine (Paxil) *, n) *, phenobarbital, phenytoin (Dilantin), sertraline (Zoloft), *, vilazodone (Viibryd) *		
Oncologic	tamoxifen ++			
Pain	carisoprodol ++ (Som (Nucynta)	a), ibuprofen *, meperidine (Demerol), methadone, tapentadol		

⁺⁺ Pro-drug; may not be effective in Poor Metabolizers due to inability to metabolize and produce active metabolite

METHOD SUMMARY

Genetic analysis was performed via Real-Time Polymerase Chain Reaction (PCR). Genotyping for Single Nucleotide Polymorphism (SNP) was performed using TaqMan® SNP Genotyping Assays, following the extraction of the DNA. For CYP2D6, a separate and distinct PCR reaction was performed, using a TaqMan® Copy Number Assay, to measure the number of CYP2D6 copies. The genetic variation and mutation analysis was performed at Omni Health Diagnostics in accordance with the protocols developed by Omni Health Diagnostics. This test is a Laboratory Developed Test (LDT) and has not been approved by the U.S. Food & Drug Administration.

Patient: Report, Gastro

LOCI / MUTATIONS TESTED

ABCB1:

CYP2C19: *1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *17

CYP2C9: *1, *2, *3, *4, *5, *6, *11

CYP2D6: *1, *2, *3, *4, *5, *6, *7, *8, *9, *10, *12, *14, *17, *29, *41

© Copyright SmartPGX, LLC 2024. All rights reserved.

Accession: P241070003

Page: 16 of 17

^{*} The enzyme encoded by this gene is a minor metabolic pathway for this drug (of minor clinical importance)



NAME : Report, Gastro ACC # : P241070003 DOB : 1/1/2001

SEX:

FINAL REPORT REVIEWED AND RELEASED BY:

Omni Health Diagnostics Lab Director: Akhtar Afshan Ali

Address: 1840 N Greenville Suite 176 Richardson, TX 75081

Richardson 75081 TX

Phone:

CLIA #: 45D2089485

Limitation: This test will not detect all the known alleles that result in altered or inactive tested genes. This test does not account for all individual variations in the individual tested. Absence of a detectable gene mutation does not rule out the possibility that a patient has different phenotypes due to the presence of an undetected polymorphism or due to other factors such as drug-drug interactions, comorbidities and lifestyle habits. This assay does not detect the decreased activity CYP2C9*8 (rs7900194) allele and may potentially misclassify CYP2C9 intermediate or poor metabolizers as normal metabolizers. CYP2C9*8 is most prevalent in African populations with an allele frequency of up to 5% (Pratt VM, et al. J Mol Diagn. 2019).

Methodology: PCR based assays detect listed alleles, including all common and most rare variants with known clinical significance at analytical sensitivity and specificity > 99%. The assays were developed to detect polymorphisms in genes encoding drug metabolism enzymes (DMEs) and associated transport proteins. This panel provides coverage of essential, commonly studied markers within CYP2D6, CYP2C9, CYP2C19, and other important DME and clinical research genes.

SmartPGx Disclaimer: The information presented on this report is provided as general educational health information. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Only a physician, pharmacist or other healthcare professional should advise a patient on the use of the medications prescribed. The pharmacogenetic assay involves use of reporting software and genotype-phenotype associations performed by SmartPGx.. The software has not been evaluated by the Food and Drug Administration. The software, and the report generated by the software, is not intended to diagnose, treat, cure, or prevent any disease. A qualified designee within the lab uses SmartPGx to generate and subsequently review the report. The pharmacogenetic report is one of multiple pieces of information that clinicians should consider in guiding their therapeutic choice for each patient. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to dose quidelines does not necessarily assure a successful medical outcome.

The information contained in this report is intended to be interpreted by a licensed physician or other licensed healthcare professional. This report is not intended to take the place of professional medical advice. Decisions regarding use of prescribed medications must be made only after consulting with a licensed physician or other licensed healthcare professional, and should consider each patient's medical history and current treatment regimen.

PATIENT INFORMATION CARD

This is summary genetic report for your patient to share with orther healthcare providers. Card can be cut out along dashed line, and carried with the patient.

Patient: Report,Gastro	_	OB: 1/2001	Requisition ID P241070003		
Pharmacogenetic Test Summary					
CYP2C19	*1/*2	Interm	ediate Metabolizer		
CYP2D6	*1/*2	Normal Metabolizer			

CYP2C9	*1/*1	Normal Metabolizer
ABCB1	A/G	Intermediate Activity

↑ Fold

© Copyright SmartPGX, LLC 2024. All rights reserved. Patient: Report, Gastro Accession: P241070003 Page: 17 of 17